Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Kimberly-Clark said CFO Nelson Urdaneta will continue as finance chief for the combined company following its pending acquisition of Kenvue. The company also named Mike Hsu as CEO and executive chairman, with Russ Torres continuing as group president and chief operating officer.
The leadership changes are tied to Kimberly-Clark’s $40 billion acquisition of Kenvue, expected to close in the latter half of 2026 subject to regulatory approval. After closing, the combined business will operate in four segments: North America; Asia Pacific Focus Markets; Europe, Middle East and Africa; and Enterprise Markets covering Latin America, India, Southeast Asia markets, and Japan.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026